Navigation Links
MedImmune Further Expands Autoimmune Disease Research Program Through Collaboration with SBI Biotech
Date:9/11/2008

GAITHERSBURG, Md. and TOKYO, Sept. 11 /PRNewswire/ -- MedImmune, the global biologics unit of AstraZeneca, and SBI Biotech Co., Ltd, a subsidiary of SBI Holdings, Inc., announced today that they have entered into a licensing and collaboration agreement to develop and commercialize SBI Biotech's anti-ILT7 protein for the potential treatment of systemic lupus erythematosus (SLE) and other autoimmune diseases. MedImmune has global rights to any resulting product candidates and will be responsible for preclinical and clinical development, as well as all future development, manufacturing, sales and marketing activities.

"It's an honor to work with Ken-ichi Arai, founder of SBI Biotech and one of Japan's leading scientists. We look forward to collaborating with him and his organization as we develop potential new treatments for autoimmune diseases such as SLE," said Anthony J. Coyle, Ph.D., vice president, research, respiratory, inflammation and autoimmunity. "As an innovative company dedicated to making a difference for patients, MedImmune will continue to seek out research and development initiatives that may address some of society's critical unmet medical needs."

Under the terms of the agreement, MedImmune is to provide SBI Biotech with an undisclosed upfront payment, milestone payments and royalties on future marketed products. SBI Biotech has granted MedImmune an exclusive license to research, develop and commercialize products that target the ILT7 protein. In addition, MedImmune will have the option to license additional targets resulting from SBI Biotech's research activities.

"We are pleased to collaborate with MedImmune, a company with strong capabilities to develop therapeutic antibodies including expertise in humanization and large-scale production. MedImmune is an excellent company and this agreement facilitates the research and development of an anti-ILT7 antibody," said Ken-ichi Arai, M.D. and Ph.D., president & CEO, SBI Biotech.
'/>"/>

SOURCE MedImmune
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. MedImmune Prepared to Support Implementation of Expanded ACIP Recommendations for Influenza Vaccinations
2. MedImmune Expands Scientific and Engineering Leadership
3. Micromet and MedImmune to Present New Clinical Data for Anti-CD19 BiTE(R) Antibody at American Society of Hematology Annual Meeting Showing Objective Clinical Responses in Relapsed Non-Hodgkins Lymphoma Patients
4. MedImmune presents new pharmaco-economic data at AAP regarding infants at high risk for RSV
5. MedImmune to present RSV surveillance and cost-effectiveness data at American Academy of Pediatrics
6. Medimmune announces phase 2 safety data for anti-RSV antibody and national RSV surveillance results
7. MedImmune Licenses Reverse Genetics Technology to GlaxoSmithKline for Use in Influenza Vaccine Development and Production
8. MedImmune Resolves FDA Observations Regarding Manufacturing Process for FluMist(R)
9. Further Acquisition for Schofield Media Group LLC
10. FTC Acts to Prevent Tobacco Industry Deception About Tar, Nicotine Levels; Congress Should Go Further by Giving FDA Authority Over Tobacco Products
11. Area Women Gather in Milford on July 10 to Further the Mission of Womens Caring Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... 23, 2014 PartnerTech Inc. , ... Lawrenceville, Georgia, welcomed Andreas von Uexkull to their facilities, ... the U.S. von Uexkull, a top trade official from ... of the U.S. to bring awareness and insight to ... Investment Partnership (TTIP). , As an expert on ...
(Date:7/23/2014)... (PRWEB) July 23, 2014 Previously, the crew ... pencil and a spreadsheet. Now, the department’s 53 ... Scheduling and Workforce Management system. , “Scheduling our personnel with ... It was hard to keep track of when people could ... this time to this time, and we would have to ...
(Date:7/23/2014)... Controlling pain during childbirth and post delivery may reduce ... a Northwestern Medicine perinatal psychiatrist, in a July 23 ... Wisner,s editorial is based on a new Chinese study ... anesthesia during a vaginal delivery had a much lower ... the epidural. , "Maximizing pain control in labor and ...
(Date:7/22/2014)... (PRWEB) July 22, 2014 Print ... Print Audit Facilities Manager web portal. Facilities Manager ... releases of the software as well as numerous ... , Print Audit Facilities Manager is a powerful, ... to remotely collect meter reads, automate supplies fulfillment ...
(Date:7/22/2014)... Recently, iFitDress.com, a popular supplier of wedding dresses and ... of white party dresses to its product category. ... now available on its website. As a special offer, all ... can get a discounted rate, up to 54% off. , ... customers, so its marketing specialist believes the new white party ...
Breaking Medicine News(10 mins):Health News:Swedish Official Tours PartnerTech’s U.S. Facility 2Health News:Swedish Official Tours PartnerTech’s U.S. Facility 3Health News:This Fire Department Allows Personnel to Schedule Themselves - Saving Administration Up To 60 Hours a Month 2Health News:This Fire Department Allows Personnel to Schedule Themselves - Saving Administration Up To 60 Hours a Month 3Health News:Controlling childbirth pain tied to lower depression risk 2Health News:Print Audit® Releases Facilities Manager 3.1.0R 2Health News:Elegant White Party Dresses Now Provided by Distinguished Company iFitDress.com 2
... , SCOTTSDALE, Ariz., July 15 ... Healthcare Trust of America, Inc.) (the "REIT"), a self-managed non-traded ... and sale agreement (the "Agreement") to acquire a 16 building ... Carolina. The transaction involves approximately 855,000 square feet of medical ...
... , , CARY, ... CRTX ), a specialty pharmaceutical company focused on ... respiratory and related markets, today announced that it has ... Drug Administration (FDA) for an extended-release antitussive product (CRTX ...
... , , , ... on the data presented today, the U.S. Food and Drug Administration (FDA) ... HCI liposome injection) and docetaxel did not provide ... or metastatic breast cancer. , , Women ...
... , WESTBROOK, Maine, July 15 IDEXX Laboratories, ... 2009 second quarter financial results for Friday, July 24, at approximately 7:00 ... 9:00 a.m. (eastern) on that day. , , ... through a link on the IDEXX Web site, www.idexx.com. An archived edition ...
... , , , ... AHS ), the leading healthcare staffing company in the United States, ... Financial Officer (CFO), effective August 10, 2009. Bailey brings nearly 30 ... insurance and pharmaceutical industries. , , Mr. ...
... method still shows promise, scientists say , WEDNESDAY, ... hopes for a minimally invasive cancer-screening technique known ... to be less effective than standard colonoscopy at ... Belgium suggests. , Although able to identify many ...
Cached Medicine News:Health News:Grubb & Ellis Healthcare REIT Signs Agreement to Purchase 16 Building Medical Office Portfolio 2Health News:Grubb & Ellis Healthcare REIT Signs Agreement to Purchase 16 Building Medical Office Portfolio 3Health News:Cornerstone Therapeutics Submits Regulatory Filing for Extended-Release Antitussive Product 2Health News:Cornerstone Therapeutics Submits Regulatory Filing for Extended-Release Antitussive Product 3Health News:Cornerstone Therapeutics Submits Regulatory Filing for Extended-Release Antitussive Product 4Health News:Cornerstone Therapeutics Submits Regulatory Filing for Extended-Release Antitussive Product 5Health News:Centocor Ortho Biotech Statement on the FDA ODAC Opinion Regarding DOXIL(R) for Treatment of Advanced Breast Cancer 2Health News:Centocor Ortho Biotech Statement on the FDA ODAC Opinion Regarding DOXIL(R) for Treatment of Advanced Breast Cancer 3Health News:Centocor Ortho Biotech Statement on the FDA ODAC Opinion Regarding DOXIL(R) for Treatment of Advanced Breast Cancer 4Health News:Centocor Ortho Biotech Statement on the FDA ODAC Opinion Regarding DOXIL(R) for Treatment of Advanced Breast Cancer 5Health News:Centocor Ortho Biotech Statement on the FDA ODAC Opinion Regarding DOXIL(R) for Treatment of Advanced Breast Cancer 6Health News:AMN Healthcare Names New Chief Financial Officer 2Health News:AMN Healthcare Names New Chief Financial Officer 3Health News: Colonoscopy Beats 'Camera Pill' at Catching Colon Cancer 2Health News: Colonoscopy Beats 'Camera Pill' at Catching Colon Cancer 3
(Date:7/22/2014)... N.J. , July 22, 2014  Vernalis plc ... achievement of proof-of-concept (POC) for CCP-08, the third ... prescription cough cold collaboration. Under this collaboration, POC ... a successful human pilot comparative study against an ... achieving POC, Vernalis will make a milestone payment ...
(Date:7/22/2014)... 2014 Quantum Materials Corporation (OTCQB:QTMM) (QMC) announced today the addition ... to the Board of Directors. QMC also announced formation of ... QMC Chief Science Officer and Board of Directors Member, along with ... University and Mr. Tomio Gotoh , a pioneer of the ... " Quantum Materials welcomes two new outside Board members, Mr. ...
(Date:7/22/2014)... July 22, 2014 ... company focused on solid dose formulations of therapeutics ... formulation of octreotide acetate achieved successful results in ... currently marketed liquid product (Sandostatin®).  Based on these ... production process to a contract manufacturing organisation (CMO), ...
Breaking Medicine Technology:Third Product in Vernalis' Cough Cold Pipeline (CCP-08) Achieves Proof-of-Concept 2Third Product in Vernalis' Cough Cold Pipeline (CCP-08) Achieves Proof-of-Concept 3Quantum Materials Announces New Outside Directors and Adds Scientific Advisory Board 2Quantum Materials Announces New Outside Directors and Adds Scientific Advisory Board 3Quantum Materials Announces New Outside Directors and Adds Scientific Advisory Board 4Glide Pharma Completes Successful Proof-of-Concept Study with Novel Solid Dose Formulation of Octreotide 2
... 22, 2011 GeNO LLC ( www.genollc.com ), ... announced commencement of  the PHiano Study: A Phase ... Hypertension in patients with Pulmonary Arterial Hypertension (PAH) ... (PH-IPF) using Inhaled NITROSYL™ nitric oxide (NO).  The ...
... March 22, 2011 Valeant Pharmaceuticals International, Inc. (NYSE: ...  J. Michael Pearson, currently Valeant,s Chief Executive Officer (CEO), as ... who remains on the Valeant Board as an independent Board ... role as CEO and has agreed to extend his contract ...
Cached Medicine Technology:GeNO LLC Initiates Study of Inhaled NITROSYL™ Nitric Oxide in Idiopathic Pulmonary Fibrosis (PH-IPF) and Pulmonary Arterial Hypertension (PAH) Patients 2GeNO LLC Initiates Study of Inhaled NITROSYL™ Nitric Oxide in Idiopathic Pulmonary Fibrosis (PH-IPF) and Pulmonary Arterial Hypertension (PAH) Patients 3
... Centuries of German Craftsmanship ... instrumentation in the world. Ocutek ... you! Only holders of the ... and eight-year apprenticeship, are qualified ...
Vertical punch designed to create a 1.5mm clean cylindrical hole. Rotatable for convenient positioning. Flat Handle. Overall length 87mm....
Adjustable piston accommodates 7-9mm trephine blade. Complete punch includes base plate, piston carrier, piston for 7 - 9mm trephine blades and 18mm diameter Teflon block. Designed for accurate donor...
... Centuries of German ... finest surgical instrumentation in ... makes them available to ... the coveted Meisterbrief certificate, ...
Medicine Products: